Cargando…
Prognostic value of PET/CT and MR-based baseline radiomics among patients with non-metastatic nasopharyngeal carcinoma
PURPOSE: Radiomics is an emerging imaging assessment technique that has shown promise in predicting survival among nasopharyngeal carcinoma (NPC) patients. Studies so far have focused on PET or MR-based radiomics independently. The aim of our study was to evaluate the prognostic value of clinical an...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9638017/ https://www.ncbi.nlm.nih.gov/pubmed/36353565 http://dx.doi.org/10.3389/fonc.2022.952763 |
_version_ | 1784825313185759232 |
---|---|
author | Kulanthaivelu, Roshini Kohan, Andres Hinzpeter, Ricarda Liu, Zhihui Amy Hope, Andrew Huang, Shao Hui Waldron, John O’Sullivan, Brian Ortega, Claudia Metser, Ur Veit-Haibach, Patrick |
author_facet | Kulanthaivelu, Roshini Kohan, Andres Hinzpeter, Ricarda Liu, Zhihui Amy Hope, Andrew Huang, Shao Hui Waldron, John O’Sullivan, Brian Ortega, Claudia Metser, Ur Veit-Haibach, Patrick |
author_sort | Kulanthaivelu, Roshini |
collection | PubMed |
description | PURPOSE: Radiomics is an emerging imaging assessment technique that has shown promise in predicting survival among nasopharyngeal carcinoma (NPC) patients. Studies so far have focused on PET or MR-based radiomics independently. The aim of our study was to evaluate the prognostic value of clinical and radiomic parameters derived from both PET/CT and MR. METHODS: Retrospective evaluation of 124 NPC patients with PET/CT and radiotherapy planning MR (RP-MR). Primary tumors were segmented using dedicated software (LIFEx version 6.1) from PET, CT, contrast-enhanced T1-weighted (T1-w), and T2-weighted (T2-w) MR sequences with 376 radiomic features extracted. Summary statistics describe patient, disease, and treatment characteristics. The Kaplan–Meier (KM) method estimates overall survival (OS) and progression-free survival (PFS). Clinical factors selected based on univariable analysis and the multivariable Cox model were subsequently constructed with radiomic features added. RESULTS: The final models comparing clinical, clinical + RP-MR, clinical + PET/CT and clinical + RP-MR + PET/CT for OS and PFS demonstrated that combined radiomic signatures were significantly associated with improved survival prognostication (AUC 0.62 vs 0.81 vs 0.75 vs 0.86 at 21 months for PFS and 0.56 vs 0.85 vs 0.79 vs 0.96 at 24 months for OS). Clinical + RP-MR features initially outperform clinical + PET/CT for both OS and PFS (<18 months), and later in the clinical course for PFS (>42 months). CONCLUSION: Our study demonstrated that PET/CT-based radiomic features may improve survival prognostication among NPC patients when combined with baseline clinical and MR-based radiomic features. |
format | Online Article Text |
id | pubmed-9638017 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-96380172022-11-08 Prognostic value of PET/CT and MR-based baseline radiomics among patients with non-metastatic nasopharyngeal carcinoma Kulanthaivelu, Roshini Kohan, Andres Hinzpeter, Ricarda Liu, Zhihui Amy Hope, Andrew Huang, Shao Hui Waldron, John O’Sullivan, Brian Ortega, Claudia Metser, Ur Veit-Haibach, Patrick Front Oncol Oncology PURPOSE: Radiomics is an emerging imaging assessment technique that has shown promise in predicting survival among nasopharyngeal carcinoma (NPC) patients. Studies so far have focused on PET or MR-based radiomics independently. The aim of our study was to evaluate the prognostic value of clinical and radiomic parameters derived from both PET/CT and MR. METHODS: Retrospective evaluation of 124 NPC patients with PET/CT and radiotherapy planning MR (RP-MR). Primary tumors were segmented using dedicated software (LIFEx version 6.1) from PET, CT, contrast-enhanced T1-weighted (T1-w), and T2-weighted (T2-w) MR sequences with 376 radiomic features extracted. Summary statistics describe patient, disease, and treatment characteristics. The Kaplan–Meier (KM) method estimates overall survival (OS) and progression-free survival (PFS). Clinical factors selected based on univariable analysis and the multivariable Cox model were subsequently constructed with radiomic features added. RESULTS: The final models comparing clinical, clinical + RP-MR, clinical + PET/CT and clinical + RP-MR + PET/CT for OS and PFS demonstrated that combined radiomic signatures were significantly associated with improved survival prognostication (AUC 0.62 vs 0.81 vs 0.75 vs 0.86 at 21 months for PFS and 0.56 vs 0.85 vs 0.79 vs 0.96 at 24 months for OS). Clinical + RP-MR features initially outperform clinical + PET/CT for both OS and PFS (<18 months), and later in the clinical course for PFS (>42 months). CONCLUSION: Our study demonstrated that PET/CT-based radiomic features may improve survival prognostication among NPC patients when combined with baseline clinical and MR-based radiomic features. Frontiers Media S.A. 2022-10-24 /pmc/articles/PMC9638017/ /pubmed/36353565 http://dx.doi.org/10.3389/fonc.2022.952763 Text en Copyright © 2022 Kulanthaivelu, Kohan, Hinzpeter, Liu, Hope, Huang, Waldron, O’Sullivan, Ortega, Metser and Veit-Haibach https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Oncology Kulanthaivelu, Roshini Kohan, Andres Hinzpeter, Ricarda Liu, Zhihui Amy Hope, Andrew Huang, Shao Hui Waldron, John O’Sullivan, Brian Ortega, Claudia Metser, Ur Veit-Haibach, Patrick Prognostic value of PET/CT and MR-based baseline radiomics among patients with non-metastatic nasopharyngeal carcinoma |
title | Prognostic value of PET/CT and MR-based baseline radiomics among patients with non-metastatic nasopharyngeal carcinoma |
title_full | Prognostic value of PET/CT and MR-based baseline radiomics among patients with non-metastatic nasopharyngeal carcinoma |
title_fullStr | Prognostic value of PET/CT and MR-based baseline radiomics among patients with non-metastatic nasopharyngeal carcinoma |
title_full_unstemmed | Prognostic value of PET/CT and MR-based baseline radiomics among patients with non-metastatic nasopharyngeal carcinoma |
title_short | Prognostic value of PET/CT and MR-based baseline radiomics among patients with non-metastatic nasopharyngeal carcinoma |
title_sort | prognostic value of pet/ct and mr-based baseline radiomics among patients with non-metastatic nasopharyngeal carcinoma |
topic | Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9638017/ https://www.ncbi.nlm.nih.gov/pubmed/36353565 http://dx.doi.org/10.3389/fonc.2022.952763 |
work_keys_str_mv | AT kulanthaiveluroshini prognosticvalueofpetctandmrbasedbaselineradiomicsamongpatientswithnonmetastaticnasopharyngealcarcinoma AT kohanandres prognosticvalueofpetctandmrbasedbaselineradiomicsamongpatientswithnonmetastaticnasopharyngealcarcinoma AT hinzpeterricarda prognosticvalueofpetctandmrbasedbaselineradiomicsamongpatientswithnonmetastaticnasopharyngealcarcinoma AT liuzhihuiamy prognosticvalueofpetctandmrbasedbaselineradiomicsamongpatientswithnonmetastaticnasopharyngealcarcinoma AT hopeandrew prognosticvalueofpetctandmrbasedbaselineradiomicsamongpatientswithnonmetastaticnasopharyngealcarcinoma AT huangshaohui prognosticvalueofpetctandmrbasedbaselineradiomicsamongpatientswithnonmetastaticnasopharyngealcarcinoma AT waldronjohn prognosticvalueofpetctandmrbasedbaselineradiomicsamongpatientswithnonmetastaticnasopharyngealcarcinoma AT osullivanbrian prognosticvalueofpetctandmrbasedbaselineradiomicsamongpatientswithnonmetastaticnasopharyngealcarcinoma AT ortegaclaudia prognosticvalueofpetctandmrbasedbaselineradiomicsamongpatientswithnonmetastaticnasopharyngealcarcinoma AT metserur prognosticvalueofpetctandmrbasedbaselineradiomicsamongpatientswithnonmetastaticnasopharyngealcarcinoma AT veithaibachpatrick prognosticvalueofpetctandmrbasedbaselineradiomicsamongpatientswithnonmetastaticnasopharyngealcarcinoma |